Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Urologia Internationalis|March 1, 2017
Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral ResectionYuki Nakamura, Soichiro Yoshida, Hiroshi Tanaka, et al.Clinical Genitourinary Cancer|May 5, 2015
High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing ProtocolKenji Tanabe, Soichiro Yoshida, Fumitaka Koga, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|December 21, 2022
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective studyKeita Izumi, Masaharu Inoue, Satoshi Washino, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|March 1, 2023
Peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot-assisted radical prostatectomyTakahiko Soma, Shohei Fukuda, Yusuke Matsuyama, et al.Anticancer Research|April 27, 2024
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial CancerHirotaka Fuchizawa, Kiyohiro Ando, Noriko Motoi, et al.Urologic Oncology|November 19, 2025
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter studyYuta Sano, Masaharu Inoue, Satoshi Washino, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 6, 2023
A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder CancerYasunobu Sekiguchi, You Nishimura, Hiroaki Kanda, et al.Biochemical and Biophysical Research Communications|July 30, 2023
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinomaKiyohiro Ando, Ryo Kurashina, Noriko Motoi, et al.International Journal of Clinical Oncology|July 24, 2024
Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumabTakayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.International Journal of Clinical Oncology|September 2, 2023
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysisSatoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.Pageof 6